ER、EGFR、P53在乳腺癌中的免疫组化研究  

Immunohistochemical Study of ER, EGFR and P53 in Breast Cancer

作　　者：刘丽 白春侠 曹美荣 LIU Li;BAI Chunxia;CAO Meirong(Yingkou Central Hospital,Yingkou 115000,China)

机构地区：[1]营口市中心医院,辽宁营口115000

出　　处：《中国医药指南》2021年第2期98-99,共2页Guide of China Medicine

摘　　要：目的探讨ER、EGFR、P53在乳腺癌的免疫组化研究中的临床表现效果。方法选取我院2018年5月至2019年5月收治的156例原发性乳腺癌患者为研究对象,在患者原发乳腺癌组织中,观察其雌激素受体(ER)、表皮生长因子受体(EGFR)、P53的表达水平,统计其阳性表达率与临床分期的相关性因素。结果 ER与临床分期及腋淋巴结转移情况呈现明显的负相关性;EGFR与其临床分期及腋淋巴结转移情况呈现明显的正相关性,与ER呈明显负相关性。结论 ER、EGFR、P53可以判断乳腺癌疾病的预后情况,能够为患者的针对性治疗提供可靠的依据。Objective To investigate the clinical manifestations of ER, EGFR and P53 in immunohistochemical study of breast cancer. Methods One hundred fifty-six patients with primary breast cancer admitted to our hospital from May 2018 to May 2019 were selected as the subjects. The expression levels of estrogen receptor(ER), epidermal growth factor receptor(EGFR) and P53 in primary breast cancer tissues were observed, and the correlation factors between the positive expression rate and clinical stages were counted. Results ER was significantly negatively correlated with clinical stage and axillary lymph node metastasis;EGFR wa significantly positively correlated with clinical stage and axillary lymph node metastasis, and wa significantly negatively correlated with ER. Conclusion ER, EGFR, and P53 can judge the prognosis of breast cancer disease, and can provide a reliable basis for targeted treatment of patients.

关 键 词：乳腺癌 雌激素受体 表皮生长因子受体 阳性表达率 

分 类 号：R737.9[医药卫生—肿瘤]